Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not a problem. Todos is a phenomenal speculation/investment with much potential. I appreciate anyone who is interested in the company and can provide insight...good or bad...and asks probing questions. We can all learn on this forum.
This is going to be a huge humanitarian problem nationwide, but another opportunity for Todos to help mankind.
NYC correction captain who works on Rikers Island contracts monkeypox
https://nypost.com/2022/08/05/nyc-doc-captain-who-works-on-rikers-island-contracts-monkeypox/?utm_campaign=applenews&utm_medium=inline&utm_source=applenews
Sorry, I didn't realize it was a rhetorical question you were asking...since you already knew the answer.
According to the S-1 dated 7/28/2022 GC is still holding 78,025,645 shares for Amarantus. See page 76 of the S-1.
https://investor.todosmedical.com/sec-filings/all-sec-filings##document-423-0001493152-22-020454-2
Benzinga Interview with Gerald from yesterday...Todos starts about the 7:50 minute mark.
SEC Form 8-K filed today...regarding annual meeting and voting:
https://investor.todosmedical.com/sec-filings/all-sec-filings##document-427-0001493152-22-021493-2
I find it really interesting that Todd Pickles is the lead attorney representing Mark against the government. Recall that over the years investors were assured that Arrayit didn't have a problem with the SEC regarding late filings etc. because of the involvement of Pickles as the company's attorney. Note: "As a former assistant United States attorney in the Criminal Division of the U.S. Attorney’s Office for the Eastern District of California, Todd’s experience includes investigations and prosecutions related to securities fraud, investment fraud, bank fraud, health care fraud, and identity fraud. Given this experience, Todd regularly provides commentary to news media concerning on-going criminal matters."
Unfortunately, games are played.
You may be right...or wrong. I don't know. Certainly there was little interest in the interview with just a few hundred watching. However, I did find it interesting and informative.
True...but there are lots of folks who follow TOMDF who aren't on Twitter.
Benzinga on Todos coming up soon on:
If you look at the trading over the past couple of years most of the volume has been in the 0.03-0.06 range. There was one fluke trade on 01/13/2020 at 0.644 which was supposed to have been 0.0644. It did trade higher in 2017 and 2018 but on very low volume and before the significant dilution occurred. But you are correct...it is still uphill for many of us who have owned the stock for years.
Looking at level 2...nice start this morning.
JFB...once again, thanks for your postings. It seems that GC's frustrations with the system are more apparent and he is more vocal on policy shortcomings.
Thank you for your thoughtful response.
Thanks, American Battery Technology has had quite a ride during the past two years. Over 300 million shares traded when it hit 4.90 in Jan 2021 but downhill from there...closed at $0.845 today. But it was a great call in 2020 at 0.03. We can hope for a positive trend in TOMDF through Jon's involvement. Thanks again.
Biden administration declares monkeypox outbreak a public health emergency in the U.S.
https://www.cnbc.com/2022/08/04/biden-administration-will-declare-monkeypox-outbreak-a-public-health-emergency-in-the-us.html
I'm very familiar with Jon Najarian and his background...just not familiar with the stock you alluded to...but thanks.
can you provide the name of the stock that went from 0.03 to 5.00?
From HHS:
"Biden–Harris Administration Releases Two New Reports on Long COVID to Support Patients and Further Research"
https://www.hhs.gov/about/news/2022/08/03/biden-harris-administration-releases-two-new-reports-long-covid-support-patients-further-research.html
Potentially positive development for Todos.
Travis, you seem to be somewhat positive about Mark's ability to mount a defense against Count One: Conspiracy to Commit Health Care Fraud...but what about Count Two: Securities Fraud?
You appear to be new to the TOMDF board. There are many on this board who have purchased many millions of shares at prices well above $0.06/share. We still believe in the future of the company and will be holding for much higher prices. There may be flippers, as with any stock, but the future of this small company is very bright and once its toxic debt issues are resolved, substantial gains should be realized.
Buzz on the Street:
New Press Release today: Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
https://investor.todosmedical.com/news-events/press-releases/detail/209/todos-medical-announces-preprint-of-acute-covid-19-paxlovid
From Reuters: 'Living with COVID': Where the pandemic could go next
https://www.reuters.com/business/healthcare-pharmaceuticals/living-with-covid-where-pandemic-could-go-next-2022-08-01/
Wouldn't that be great, but I think it is highly unlikely.
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
(see article below)
More confirmation that Tollovid may be needed for Paxlovid and Molnupiravir to be fully effective in combating Covid.
https://pubmed.ncbi.nlm.nih.gov/35794889/#:~:text=0.77%25%20for%20hospitalizations.-,The%207%2Dday%20and%2030%2Dday%20COVID%2D19%20rebound,%25%20and%201.39%25%20for%20hospitalizations
Thanks for your response.
Considering your prior involvement with the authorities, are you going to testify at the trial?
Promising development and good explanation of the new relationship by GC.
Certainly a lot to digest from the S-1.
The whole issue of dosing needs clarification and updating. Your comment about popping a couple Tollovid when entering a high risk situation is noteworthy. I recall that Dr. Arad said that she would take six pills during similar situations.
Arp,
Thank you for your comments and assessment of Todos and GC. I also share the concerns you highlighted. The salary issues need to be addressed by the Chairman of the Board, Dr. Herman Weiss, the Board of Directors, and its Compensation Committee...and shareholders. Your last paragraph is especially prescient regarding public relations and optics. I remain optimistic about the company but the business plan requires greater focus and execution needs to dramatically improve.
Regards,
Sloan
Arp,
Good points...great to see you posting again.
Interesting testimony regarding Tollovid:
Heading to Seoul tonight! Looking forward to seeing this
— Gerald Commissiong (@G_Commish) July 24, 2022
It will be interesting to learn about Gerald's trip to South Korea.
Press Release:
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
https://investor.todosmedical.com/news-events/press-releases/detail/207/todos-medical-announces-preprint-of-chronic-long-covid-case
Patents...hummm. Publishing...interesting.
Thanks for the tidbits.
Although covid cases in NY, NJ, MA, and CT are currently trending lower I'm not as sanguine as you are regarding the current and future trends of covid overall. There were 650 covid deaths yesterday and 4745 people in ICU's across the country. Those numbers are still pretty significant. As we approach Fall, rates will surely rise again in your area, especially with the new variants. I don't think it would be wise to become too cavalier when it comes to covid...as I did in May while visiting Florida. I caught covid while competing in a a track and field event. Fortunately, Tollovid helped me through the illness fairly quickly.
https://charts.medriva.com/us